The Dementia Consortium connects academia and pharma industry to develop novel drug targets for dementia, Alzheimer’s, Parkinson’s and Huntington’s disease and help them progress towards the clinic. Credit: Pixabay.

Charity industry partnership Dementia Consortium has announced that pharmaceutical companies, Johnson & Johnson Innovation, Takeda and research organisation Evotec have joined its drug discovery collaboration for neurodegenerative diseases.

The consortium provides a cost and risk sharing solution for target validation and encourages international collaborations between academic researchers and pharmaceutical companies to translate novel drug targets for dementia, Alzheimer’s, Parkinson’s and Huntington’s disease towards the clinic.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The Dementia Consortium currently connects Alzheimer’s Research UK with AbbVie, Astex Pharmaceuticals, Eisai, Eli Lilly and Merck. There are seven projects being supported by the partnership – for example, two target the immune system to halt nerve damage and another investigating the role of TDP-43 build-up in brains of patients with frontotemporal dementia and motor neurone disease.

Johnson & Johnson subsidiary Janssen Research and Development neurodeneration disease area stronghold area leader Sir Simon Lovestone said: “We are delighted to collaborate as part of the Dementia Consortium, and we believe this is an exciting approach to identify novel targets for drug discovery in neurodegeneration, with the ultimate goal of helping patients all over the world who suffer from debilitating central nervous system disorders.”

Alzheimer’s Research UK director of research Dr Carol Routledge said: “We’re excited to welcome Johnson & Johnson Innovation, Takeda Pharmaceuticals and Evotec to the Dementia Consortium as we look to build on the excellent work it has achieved so far.

“The Dementia Consortium will give new opportunities for world-leading academic researchers to develop their novel and promising findings into treatments. Supporting these projects is vital in helping make scientific breakthroughs possible and bringing about a new life-changing dementia treatment.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The consortium is looking to support further drug discovery projects that focus on new molecular targets with evidence of a potential therapeutic effect for neurodegenerative diseases.

Projects are usually awarded between £100,000 and £250,000, with £500,000 being the limit for particularly novel cases.